Singapore-based Basel Medical Group (BMGL) announced plans to acquire $1 billion worth of Bitcoin (BTC) to strengthen its balance sheet and accelerate expansion across Asian markets.
Basel also revealed that the proposed transaction is being negotiated with a consortium of institutional investors and high-net-worth individuals active in the crypto sector.
Basel CEO Darren Chhoa said the $1 billion acquisition would give the firm “unprecedented capacity” to execute its Asia growth strategy.
He added that capital infusion would create one of the strongest balance sheets among Asia-focused medical providers, enabling it to pursue mergers and acquisitions and enhance its financial resilience.
The firm described the initiative as a “landmark transaction” that would represent one of the largest Bitcoin allocations by a healthcare group in the Asia-Pacific region.
The announcement highlighted an intention to finalize the deal within the current quarter, subject to regulatory approval and standard closing conditions.
Transaction structure and strategic objectives
The proposed acquisition will occur through a share-swap arrangement with external investors, rather than a direct cash purchase of Bitcoin from reserves. Basel stated that this model offers enhanced capital efficiency while preserving liquidity for healthcare operations.
The company’s management sees the diversification into Bitcoin as a hedge against currency volatility and inflation risks in emerging markets, particularly in regions where it seeks to expand.
BMGL also sees the acquisition as a mechanism to attract strategic partnerships in the healthcare and digital asset sectors.
Basel’s leadership said it would provide additional details upon the transaction’s completion and remain committed to regulatory compliance in all jurisdictions where it operates.
Market reaction diverges from Bitcoin trend
Despite Basel’s framing of the move as a financial strengthening initiative, the company’s stock price declined sharply following the announcement.
Its shares fell to a low of $2.10 despite climbing 68% earlier in the day to a high of $3.41 from the daily opening price of $2.84. The volatility adds to the massive 57% drawdown observed on May 14.
Despite the tumultuous price action for the day, the share price mounted a recovery before the trading day ended to close the day down 9.89% to $2.37 as of press time.
The reaction contrasts with recent market behavior in other firms announcing Bitcoin strategies.
On March 12, Rumble saw its stock price rise 5% after announcing a Bitcoin acquisition. Japanese firm Metaplanet gained nearly 20% in a single session on July 22 after disclosing a purchase of more than 20 BTC.
HK Asia Holdings surged 92.98% on Feb. 13 after acquiring 1 BTC for approximately $96,150. Meanwhile, Brazilian fintech Méliuz gained 16.3% on March 6 after detailing its Bitcoin investment framework,
While Basel’s initial market response diverged from those precedents, the company maintains that the transaction is part of a broader financial restructuring initiative rather than a speculative bet.
Mentioned in this article
#Basel #Medical #Group #add #Bitcoin #treasury #falling #share #prices
